Symbiotec Pharmalab IPO Subscription Day 1: Issue Subscribed 0.85x, Retail and NII Cross 1x

Mumbai, August 24: The Symbiotec Pharmalab IPO saw a significant pickup in demand as the first day of bidding progressed on Monday, August 24, 2026. By 5:06 PM on Day 1, the ₹1,757 crore IPO was subscribed 0.85 times overall. 

The retail category managed to cross full subscription, reaching 1.01 times, while the NII portion was subscribed 1.10 times. QIB (Ex Anchor) participation remained comparatively lower at 0.37 times. 

The issue received bids for 1,05,56,535 shares against 1,24,60,533 shares offered, with total applications reaching 3,40,001. 

Symbiotec Pharmalab IPO subscription status 

Here is the category-wise subscription position at 5:06 PM on August 24: 

The sNII category was the strongest among the main investor segments, with subscription reaching 1.66 times. The employee quota was also subscribed 1.65 times. 

Within the NII segment, the larger bNII category remained below full subscription at 0.82 times, while the smaller sNII segment had already received bids for 14,75,895 shares against 8,87,652 shares available. 

Day-wise subscription details 

The IPO opened for subscription on August 24, 2026, and the Day 1 numbers show how demand built up during the session. 

With just Day 1 completed, retail and NII investors have already taken their respective portions past the 1x mark. The remaining subscription momentum will largely depend on how the QIB category responds over the next two sessions. 

IPO price band and investment required 

Symbiotec Pharmalab has fixed the IPO price band at ₹938 to ₹988 per share. The minimum application size is 15 shares, meaning a retail investor needs ₹14,820 at the upper end of the price band to apply for one lot. 

Investors can bid in multiples of 15 shares. The maximum retail application is 195 shares, or 13 lots, requiring ₹1,92,660 at the upper price. 

The company has also reserved 33,408 shares for employees, who are eligible for a ₹90 per share discount to the issue price. 

Symbiotec Pharmalab IPO issue details 

The IPO comprises a fresh issue of 15,21,261 shares worth ₹150 crore and an offer for sale of 1,62,65,181 shares worth ₹1,607 crore at the upper price band. 

The total issue size stands at 1,77,86,442 shares, aggregating to around ₹1,757 crore. 

The issue opened on August 24 and will remain open until August 27, 2026. The tentative allotment date is August 28, followed by the expected refund and credit of shares on August 31. The shares are scheduled to list on September 1, 2026, on both NSE and BSE. 

IPO reservation 

After excluding the employee reservation, the net offer to the public is divided across the three main investor categories. 

• QIB: 50% of the net offer 

• NII: 15% of the net offer 

• Retail: 35% of the net offer 

The IPO also had an anchor allocation of 53,25,909 shares, with Symbiotec Pharmalab raising ₹526.20 crore from anchor investors ahead of the public issue. 

About Symbiotec Pharmalab 

Symbiotec Pharmalab Ltd. was incorporated in 2002 and operates in the pharmaceutical and biotechnology sector. The company develops and manufactures active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products for domestic and international markets. 

According to the company information, Symbiotec Pharmalab has more than three decades of industry experience and has grown from a lab-scale steroid hormone API manufacturer into an industrial-scale, backward-integrated manufacturing platform. Its products have regulatory approvals from agencies and organisations across several international markets. 

What to watch on Day 2 

The Day 1 numbers give the IPO a decent start, but the picture is still incomplete. Retail and NII demand has crossed the 1x mark, while QIB demand is only at 0.37x. 

The key number to track on Day 2 will therefore be QIB participation. If institutional bidding picks up alongside continued retail and HNI demand, the overall subscription could accelerate sharply toward the final day. 

For now, Symbiotec Pharmalab IPO stands at 0.85x subscription after Day 1, with the sNII and employee categories showing the strongest demand.  

Source: 

• https://www.nseindia.com/market-data/issue-information?symbol=SYMBIOTEC&series=EQ&type=Active